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EFECTO DE UNA SUPLEMENTACIÓN LÁCTEA CON
ÁCIDO LINOLEICO CONJUGADO SOBRE EL CONTROL
DE PESO Y LA COMPOSICIÓN CORPORAL DE
PERSONAS SANAS CON SOBREPESO
Resumen
Introducción: Los ácidos linoleicos conjugados (ALC) han
mostrado unos efectos beneficiosos en el tratamiento del control
de peso; sin embargo, esta relación no está clara.
Objetivo: El propósito de este estudio fue examinar los efectos y
la seguridad de 3 g de una mezcla 1:1 de c9-t11 y t10-c12 sobre el
control de peso y la composición corporal en individuos sanos con
sobrepeso.
Métodos: Se realizó un estudio clínico prospectivo, de grupos
paralelos, de distribución aleatoria, a doble ciego y con control
placebo, de 24 semanas de duración, en 38 voluntarios (29 muje-
res, 9 hombres) con edades de 30-55 años y un IMC ≥27- < 30
kg/m2 que consumieron 200 ml/día de leche desnatada con 3 g de
ALC o 3 g de aceite de oliva (placebo). Se midieron datos de
antropometría, bioquímica y absorciometría dual de rayos X
(DXA). Se evaluaron la dieta y la actividad física.
Resultados: Los sujetos mantuvieron sus patrones habituales
de dieta y ejercicio a lo largo del estudio. Sólo el grupo de ALC
mostró una reducción significativa del peso (74,43 ± 10,45 vs
73,54 ± 11,66 kg, p = 0,029) y de la circunferencia de la cintura
(91,45 ± 10,33 vs 90,65 ± 9,84 cm, p = 0,012) entre el periodo
basal y el final del estudio. El IMC y el cociente cintura/talla dis-
minuyeron (28,44 ± 1,08 vs 27,81 ± 1,43 kg/m2, p = 0,030 y 0,57 ±
0,05 vs 0,56 ± 0,04 p = 0,013, respectivamente) en el grupo ALC
al final del estudio. El grupo ALC experimentó una reducción
de la masa grasa total tras 24 semanas (38,62 ± 5,02 vs 36,65 ±
5,64 %, p = 0,035). No se observó reducción en el grupo control.
El índice HOMA no experimentó cambios.
Conclusiones: El consumo de leche desnatada enriquecida
con 3 g de una mezcla 1:1 de c9-t11 y t10-c12 durante 24 semanas
produjo un descenso del peso corporal y la masa grasa total en
sujetos sanos con sobrepeso que mantuvieron sus patrones habi-
tuales de dieta y ejercicio físico. No se observaron efectos adver-
sos. Registrado con el identificador núm. NCT01503047 en Clini-
calTrials.gov.
(Nutr Hosp. 2013;28:2090-2098)
DOI:10.3305/nh.2013.28.6.7013
Palabras clave: Ácido linoleico conjugado. Sobrepeso. Pérdida de
peso. Absorciometría Dual de Rayos X. Ensayos clínicos.
Abstract
Introduction: Conjugated linoleic acids (CLAs) have
shown beneficial effects in weight control therapy however
this relation is not clear.
Objetive: The aim of the study was to examine the effects
and safety of 3 g of a 1:1 mix of c9-t11 and t10-c12 on weight
control and body composition in healthy overweight indivi-
duals. 
Methods: A prospective, placebo-controlled, randomised
double-blind, parallel clinical trial lasting 24 weeks was
carried out in 38 volunteers (29w, 9m) aged 30-55 years and
BMI ≥27-<30 kg/m2 who consumed 200 ml/day of skimmed
milk with 3g of CLAs or 3g olive oil (placebo). Anthropome-
tric, biochemical and dual x-ray absorptiometry (DXA)
tests were measured. Diet and physical activity were
assessed. 
Results: Subjects maintained their habitual dietary and
exercise patterns over the study. Only CLA group showed a
significant decrease in weight (74.43 ± 10.45 vs 73.54 ± 11.66
kg, p = 0.029) and waist circumference (91.45 ± 10.33 vs
90.65 ± 9.84 cm, p = 0.012) between baseline and end of the
study. BMI and waist height ratio decreased (28.44 ± 1.08 vs
27.81 ± 1.43 kg/m2, p = 0.030 and 0.57 ± 0.05 vs 0.56 ± 0.04 p
= 0.013 respectively) in CLA group at the end. CLA group
experienced a reduction in total fat mass after 24 weeks
(38.62 ± 5.02 vs 36.65 ± 5.64%, p = 0.035). No decrease was
observed in Control group. HOMA index had no changes. 
Conclusions: The consumption of skimmed milk enri-
ched with 3g of a 1:1 mixture of c9-t11 and t10-c12 for 24
weeks led to a decrease in body weight and total fat mass in
healthy, overweight subjects who maintained habitual
diets and exercise patterns. No adverse effects were
observed. Registered under ClinicalTrials.gov Identifier
No. NCT01503047.
(Nutr Hosp. 2013;28:2090-2098)
DOI:10.3305/nh.2013.28.6.7013
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Introduction
The conjugated linoleic acids (CLAs) form a family
of 28 positional and geometric isomers with conjugated
bonds of linoleic acid. CLAs are formed naturally via
the biohydrogenation of fats by bacteria in the gastroin-
testinal tract of ruminants. This involves changing the
position and configuration of the double bonds of
PUFAs, thus producing, for example, trans-10, cis-12
(t10-c12) or cis-9, trans-11 (c9-t11) octadecadienoic
acid1, the CLA isomers of greatest biological activity2. 
Milk, milk products and meat products from rumi-
nants are the major food sources of CLAs; humans can
synthesise them but only in small amounts3. The c9-t11
isomer, which accounts for nearly 90% of all naturally
occurring CLAs, has been attributed anti-carcinogenic
effects while t10-c12, found in much smaller amounts
(around 10%), appears to be responsible for changes in
lipid metabolism and body composition4. The health
benefits of these isomers might be obtained via dietary
supplementation with the appropriate quantities and
proportions. Early studies suggested that the intake of
3.4 g/d CLAs is effective in helping body weight
control, with higher intakes achieving no greater
effect5. 
Over the last 30 years, the prevalence of overweight
and obesity has doubled across the globe, and the world
is now home to some 500 million obese adults and
nearly a billion more who are overweight6. Both are
associated with an increased risk of death7 and more effi-
cient overweight treatment should be a priority in public
health. The possible beneficial effects of CLAs on coad-
juvants in weight control therapy have therefore
attracted much attention. A number of studies have been
performed to determine the effects of CLAs on body
composition, with special emphasis on their effects on
fat and lean mass8. With respect to weight control, trials
involving the consumption of skimmed milk supple-
mented with the 1:1 mix of c9-t11 and t10-c12 for 12
weeks9 suggest such behaviour to be beneficial.
However, some authors also reported CLAs have no
effects on body composition10 or increase the risk of
insulin resistance and cardiovascular disease, to increase
in inflammation-mediating molecules such as C-reac-
tive protein, TNF-α, IL6, adiponectin and leptin11. The
reasons for such discrepancies probably lie in diffe-
rences in the characteristics of the different trials, which
have involved different isomers, doses and anthropome-
tric techniques, as well as the background food matrix in
which these CLAs were provided, besides of gender and
characteristics of the subjects, from here that trials using
a standardised methodology are needed. 
Due to lack of evidence on previous stages to obesity
the aim of the present study was to examine the effects
and safety of consuming 200 ml/day of skimmed milk
supplemented with 3 g of a 1:1 mix of c9-t11 and t10-
c12 (Tonalin®) on weight control and body composition
over 24 weeks in healthy overweight individuals who
maintained their habitual dietary and exercise patterns.
Subjects and methods
Approval
Study subjects
Subjects were recruited by the Clinical Nutrition and
Dietetic Department, (La Paz University Hospital,
Madrid, Spain) via information pamphlets, press rele-
ases, and/or e-mails. The study included 42 volunteers
(32 women and 10 men) aged 30-55 years and suffered
grade II overweight (body mass index, BMI≥27 but <30
kg/m2). The requirements of inclusion were that subjects
should not be adhered to any calorie restriction diet, be
taking any weight control medication, or have lost more
than 5 kg in the three months prior to the study; these
conditions were met by all subjects. The exclusion
criteria were the suffering of serious concomitant disease
such as diabetes mellitus type II, metabolic syndrome
(according to the criteria of the Adult Treatment Panel
III), cancer, kidney disease, HIV, tuberculosis, cardio-
vascular disease, chronic obstructive pulmonary disease,
eating disorders, having undergone bariatric surgery
and/or intestinal resection, and pregnancy. All subjects
gave their signed, informed consent to be included in the
study, as required by the latest version of the Helsinki
declaration12. The study was approved by the Scientific
Research and Ethics Committee of the La Paz University
Hospital. This trial was registered at clinical trials.gov as
NCT01503047.http://clinicaltrials.gov/.
Study design and milk products
This study was designed as a prospective, placebo-
controlled, randomised double-blind, parallel clinical
trial lasting 24 weeks. Treatment consisted of exchan-
ging the normal milk product consumed at breakfast
for 200 ml of a skimmed milk with a lipid composition
of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic
acid, enriched with 3 g of a 1:1 mix of c9-t11 and t10-
c12 (Tonalin®) (CLA group; n = 22), or a placebo drink,
containing 200 ml of the same skimmed milk but
without added CLAs, compensating for their absence
with 3 g oleic acid (placebo, Control group, n = 20).
Both milks provided 49 kcal/100 ml to the habitual
diet. Special care was taken to ensure that both the
CLA and P product had the same organoleptic quali-
ties. The blinding of these products were undertaken by
the supplying company, with both provided in identical
200 ml impermeable cartons. 
Over the 24 weeks experimental period, the study
subjects attended six appointments (one per month) at
the Clinical Nutrition and Dietetic Department, La Paz
University Hospital in Madrid. During the first visit
they were randomly assigned a “treatment number”
consisting of three digits, which placed them in either
the CLA or Control group. Neither the subjects nor the
researchers knew to which treatment group the subjects
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had been assigned; the researchers were unblinded
only at the end of the study. The subjects also under-
went anthropometric, biochemical and dual X-ray
absorsptiometry (DXA) tests (see below), their diets
were examined, and their physical activity recorded.
During visits 2-5 their adherence to the consumption of
the supplemented milk was determined, as well as their
tolerance of it. Any variation in the diet and body
weight was also recorded, along with any adverse
events. On the sixth visit the tests performed during the
first appointment were repeated.
Diet and exercise
It was made very clear to the study subjects that they
should keep to their habitual dietary and exercise habits
during the experimental period. The diet of each
subject was monitored at each of the six appointments.
All food and beverages consumed were recorded in the
week prior to each appointment using a food frequency
questionnaire and a “3-day food and drink record” vali-
dated for the Spanish population13. All food and drinks
consumed at home and away for three consecutive
days, including a weekend day were recorded. Subjects
were instructed to register the weights of food
consumed if possible and to use household measure-
ments (spoonfuls, cups, etc) if not. At each visit, every
record was thoroughly reviewed by a nutritionist and
the participant in order to complete the information and
avoid the forgetfulness in the register of foods. The
energy and nutritional content of the food consumed
was then calculated using DietSOURCE® v.3.0 soft-
ware. The values obtained were compared to the
recommended values to determine dietary adequacy14.
Physical activity was determined using an activity
questionnaire, validated for the Spanish population15,
covering the seven days prior to each appointment. 
Anthropometric measurements and body composition
Anthropometric measurements were made using
standard techniques and adhering to international
norms set out by the WHO16. All measurements were
made by trained personnel, first thing in the morning,
with the subjects barefoot and wearing only underwear.
Body weight was determined using a single frequency
body composition analyser (TANITA BC-420MA,
Biologica Tecnología Médica S.L. Barcelona, Spain),
with subjects standing upright and with heels together.
Height was determined using a height meter with an
accuracy of 1 mm (range 80-200 cm), again with the
subject standing upright, and with the head in the
Frankfurt plane. 
Waist circumference (WC) was measured midway
between the lowest lateral border of the ribs and the
upper lateral border of the iliac crest, following normal
expiration, using a non-stretchable metallic tape accu-
rate to 1 mm. All measurements were made in triplicate
by the same observer and the mean was calculated. 
The values recorded were used to determine the BMI
(body weight in kg/height in m2) and the waist/height
ratio (WHR; WC in cm/height in cm). 
Body composition was determined by DXA (Gene -
ral Electric. Madison, Wisc, USA) a technique that
distinguishes between fat and lean mass content.
Subjects were examined in the supine position with
their arms at their sides.
Blood samples analysis
Blood samples were obtained from fasting subjects
at baseline and at 24 weeks, and the plasma glucose,
fasting immunoreactive insulin, total cholesterol,
HDL- and LDL-cholesterol, triglycerides, leptin,
adiponectin, C-reactive-protein, plasminogen activator
inhibitor-1, alanine amino transferase, aspartate amino
transferase and creatinine concentrations determined.
Insulin sensitivity was estimated using the HOMA-IR
index [HOMA-IR = fasting glucose (mmol/l)/fasting
immunoreactive insulin (mU/ml)/22•5]. Analyses
were performed in the laboratories of Biochemistry of
the La Paz University Hospital and Laboratory of
Molecular Biology, Nutrition and Biotechnology
(LBNB), Balearic Islands University. 
Blood pressure and heart rate
Blood pressure and heart rate were measured in the
right arm using an Automatic Monitor Welch (Allyn
Spot Vital Signs 420 series. Arizona, United States) (±
5 mmHg). Three measurements were taken at 5 min
intervals and the mean was calculated.
Compliance and adverse events
Compliance was assessed every month by comparing
the number of milk cartons provided and the number of
unopened cartons returned. A subject was considered
compliant when having consumed the contents of at
least 75% of the cartons dispensed. Potential adverse
events were asked on each visit and, if any recorded. An
adverse event was defined as any unfavourable, unin-
tended effect reported by a subject or observed by the
investigator during the study. All were recorded along
with the symptoms involved (nausea, vomiting, diarr-
hoea, bad breath, constipation). 
Statistical analysis
Data are presented as means ± standard deviation
(SD). The Kolmogorov-Smirnov test was used to
check the normal distribution of the data. Atypical data
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(i.e., lying more than two SDs from the mean) in asym-
metric distributions were deemed to reflect true results;
they were, therefore, not eliminated from the analysis.
The Levene test was used to determine whether the
variance presented by the measured variables was
homogeneous. When the distribution of the results was
normal, the Student t test was used to compare the
mean values of the studied variables recorded for the
two treatment groups. The Mann-Whitney U test was
used when the distribution was not normal. 
Differences within groups at the beginning and end
of the study were examined using the paired Student’s t
test when the distribution of the results was normal,
and the Wilcoxon test when it was not. Bonferroni
correction was used since multiple comparisons were
made. All tests were two-tailed. Significance was set at
p<0.05. All calculations were performed using SPSS
v.9.0 software (SPSS Inc.). 
Results
Thirty-eight of the 42 volunteers (90.5%) completed
the study. Four subjects (0 in CLA and 4 in Control
groups) withdrew during the intervention for personal
reasons unconnected with the study. Thus, the analyses
were conduced with 38 participants (29 women and 9
men), being 22 subjects in CLA group and 16 in
Control group (Fig. 1). The baseline characteristics of
the two study groups are summarized in the table I. The
mean age of the subjects was 44 ± 8 years, with no
significant differences between gender or treatment
groups (Table I). Analysis of dietary quality showed
that habitual energy intake profiles of subjects were
imbalanced; intake of lipids was above recommenda-
tions, at expenses of carbohydrate intake, which were
lower than recommended. In fact, just one subject had
an adequate dietary distribution of macronutrients.
The subjects successfully maintained their normal
dietary and exercise patterns over the study period
(Table II). At the beginning of the study, the anthropo-
metric and dietary characteristics of the members of the
two treatment groups were similar, with no significant
differences between them (Tables II and III). 
At the beginning of the study all the subjects had a
physical activity minor to ≤60 min/week and they were
classified as “sedentary”; there were no changes at the
end of the intervention. 
Fig. 1.—Study flow chart.
Screened
n = 50
Excluded or refuse to
participate
n = 8
Subjects randomized
n = 42
Control group
n = 20
Withdrew during intervention
n = 4
Excluded due to data
incomplete
n = 0
Data available
n = 16
CLA group
n = 22
Withdrew during intervention
n = 0
Excluded due to data
incomplete
n = 0
Data available
n = 22
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The initial mean BMI and WHR of the subjects in
both groups was similar (Table III), as were their body
fat mass in absolute values and as percentage of body
weight (Table III). 
CLA subjects showed a significant decrease in body
weight (p = 0.029) and WC (p = 0.012) between base-
line and the end of the study. The indices dependent on
these variables —BMI and WHR— also showed signi-
ficant reductions (p = 0.030 and p = 0.013 respectively)
in the CLA group by the end of the study period.
Indeed, after 24 weeks of treatment, CLA subjects had
a significantly lower weight versus Control (p < 0.05). 
At the beginning of the study, 100% of the subjects
belonging to CLA group showed grade II overweight
(BMI ≥27 but <30 kg/m2), but by the end 28.6% (6/21)
had moved to grade I (BMI ≥25 but <27 kg/m2). Inte-
restingly, the Control group showed no such trend:
although 16.6% (2/12) moved down from grade II to
grade I, another 16.6% moved up to obesity type I
(BMI ≥30 but <35 kg/m2).
Changes in body weight associated with CLA treat-
ment were also associated with significant changes in
body composition, as determined by DXA between
baseline and the end of the study (Table III). Subjects
who consumed CLA presented a decrease in total fat
mass measured by kg (p = 0.046) as well as by percen-
tage (p = 0.035); while in the Control group no reduc-
tions were observed. A significant correlation was
demonstrated between changes in body weight and fat
mass in the CLA group (r = 0.600, p = 0.03), on the
other hand no correlation was found in the Control
group (r = 0.464, p = 0.08). No changes were observed
in lean mass in either group.
Table I
Subjects characteristics at the baseline
CLA group Control group
(n = 22) (n = 20) P
Sex (female/male) 17 / 5 12 / 4 NS
Age (years) 43.00 ± 8.30 44.35 ± 7.79 NS
Weight (kg) 74.43 ± 10.45 73.88 ± 7.73 NS
BMI (kg/m2) 28.44 ± 1.08 28.56 ± 0.95 NS
WC (cm) 91.45 ± 10.33 91.48 ± 5.41 NS
WHR 0.57 ± 0.05 0.57 ± 0.03 NS
FM (kg) 28.63 ± 4.21 28.14 ± 4.26 NS
FM (%) 38.62 ± 5.02 38.49 ± 5.27 NS
LM (kg) 43.22 ± 9.70 42.17 ± 6.01 NS
Total intake
Kcal/d 1997.82 ± 385.44 1889.41 ± 341.62 NS
BMI: body mass index; FM: fat mass. LM: lean mass.WC: waist cir-
cumference. WHR: waist/height ratio. NS: no significant.
Table II
Dietary characteristics at the baseline and end of the experimental period depending on treatment
CLA group Control group
(n = 22) (n = 16)
TEE (kcal/d)   Week 0 2397.77 ± 305.04 2346.44 ± 226.66
Week 24 2413.06 ± 336.74 2384.05 ± 297.77
Variation -21.59 ± 43.97 -6.17 ± 28.16
Intake (kcal/d) Week 0 1992.82 ± 385.44 1889.41 ± 341.62
Week 24 1900.61 ± 286.11 1907.74 ± 280.25
Variation -97.20 ± 287.04 18.33 ± 254.47
Underestimation (%) Week 0 16.7 ± 16.59 20.07 ± 15.52
Week 24 19.08 ± 13.35 19.61 ± 12.04
Variation 3.01 ± 13.19 -0.92 ± 11.16
Energy profile
Proteins (%) Week 0 19.46 ± 2.77 18.76 ± 2.33
Week 24 18.92 ± 2.14 18.28 ± 1.98
Variation -0.54 ± 2.38 -0.48 ± 1.94
Carbohydrates (%) Week 0 43.58 ± 7.52 40.71 ± 8.50
Week 24 43.83 ± 5.64 43.82 ± 4.73
Variation 0.26 ± 4.02 3.11 ± 6.69
Lipids (%) Week 0 37.04 ± 6.84 40.47 ± 8.83
Week 24 37.36 ± 5.33 38.00 ± 5.20
Variation 0.32 ± 3.87 -2.48 ± 6.57
TEE, theoretical energy expenditure. 
asignificantly different with respect to values at the beginning of the study (p < 0.05).
bsignificantly different with respect to Control group (p < 0.05). 
39. EFFECTS_01. Interacción  05/12/13  12:39  Página 2094
No significant changes were demonstrated in blood
analyses, except for glucose (p = 0.002) and plasma crea-
tinine (p = 0.001) in the CLA group, both of which
showed significant increases by the end of the study
period. Nevertheless, insulin levels and HOMA index
have no changes at the end of the intervention (Table IV). 
The number of adverse events was low in both CLA
and Control groups: nausea 4.2% vs 0%, diarrhoea
4.2% vs 13.0%, constipation 12.5% vs 13.3%, bloating
12.5% vs 20.0%, and bad breath 0% vs 13.3% (no
significant differences for any comparison). No
member of either group suffered stomach acidity. 
Discussion
Many beneficial properties have been reported for
CLAs since the firsts descriptions, including protection
against cancer17, diabetes18 and obesity19. However, most
of the intervention have been conducted in subjects with
an established disease and there are no studies to observe
CLAs effect on early stages as disease prevention. 
Given the worldwide epidemic of obesity, and the
millions of obesity-related deaths that occur every year,
the potential beneficial effects of CLA consumption on
body weight and body composition have received
growing attention. CLA consumption has, for some
time now, been associated with a decrease in body fat in
overweight and obese individuals5. In later publication
involving supplementation with 500 ml skimmed milk
containing 3g of a 1:1 mixture of c9-t11 and t10-c12
administered to subjects with metabolic syndrome for
12 weeks, a significant reduction in total and trunk fat
mass in overweight was observed, with no adverse
effects9. Moreno et al20 administered CLA-enriched
milk to 572 subjects on a hypocaloric diet for 12 weeks,
and reported significant improvements in body compo-
sition with no adverse effects. However, Nazare et al
(2007)21, who administered yoghurt containing 3,76 g of
the Tonalin® mixture daily for 14 weeks to healthy,
overweight subjects, observed no changes in body
composition in terms of fat mass and fat percentage,
although they did record an increase in basal metabolic
rate. Thus after more than a decade of research, the
effects of CLAs are yet to be fully characterised. 
In the present study, a body weight reduction of 1.4 kg
was demonstrated in the CLA group. This may seem to
be clinically irrelevant, but body weight was strongly
related to fat mass in these subjects (r = 0.600). The treat-
ment therefore directly reduced the amount of total body
fat. The rate of decrease (0.02 kg/week) was lower than
that reported in a meta-analysis of 18 studies by
Whigham et al (2007)22 (0.09 kg/week). In the mean-
time, this is of interest when it is understood that, current
trend for developed countries with high prevalence of
obesity; gain an average of 0.4 kg total weight/year
(0.009 kg/week)23. Thus, while the overall reduction in
body weight was small among volunteers, the reduction
Efecto de una suplementación láctea
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Table III
Anthropometric characteristics at the baseline and end of the experimental period depending on treatment
CLA group Control group
(n = 22) (n = 16)
Body weight (kg) Week 0 74.43 ± 10.45ab 73.88 ± 7.73
Week 24 73.54 ± 11.66 74.01 ± 9.61
Variation -1.40 ± 2.82 -0.54 ± 1.95
WC (cm) Week 0 91.45 ± 10.33 91.48 ± 5.41
Week 24 90.65 ± 9.84 a 91.00 ± 5.52
Variation -2.60 ± 4.43 -0.46 ± 3.88
BMI (kg/m2) Week 0 28.44 ± 1.08 28.56 ± 0.95
Week 24 27.81 ±1.43a 28.51 ± 1.29
Variation -0.53 ± 1.06 -0.21 ± 0.81
WHR Week 0 0.57 ± 0.05 0.57 ± 0.03
Week 24 0.56 ± 0.04a 0.57 ± 0.03
Variation -0.02 ± 0.03 0.00 ± 0.03
FM (kg) Week 0 28.63 ± 4.21 28.14 ± 4.26
Week 24 27.51 ± 5.39a 26.72 ± 3.93
Variation -1.18 ± 2.74 -0.89 ± 1.89
FM (%) Week 0 38.62 ± 5.02 38.49 ± 5.27
Week 24 36.65 ± 5.64a 36.81 ± 6.20
Variation -1.02 ± 2.13 -0.44 ± 1.34
Lean mass (kg) Week 0 43.22 ± 9.70 42.17 ± 6.01
Week 24 44.69 ± 1.02 42.49 ± 7.73
Variation -0.66 ± 2.41 -0.56 ± 2.27
BMI: body mass index. FM: fat mass. LM: lean mass. WC: waist circumference. WHR: waist/height ratio.
asignificantly different with respect to values at the beginning of the study (p < 0.05).
bsignificantly different with respect to Control group (p < 0.05). 
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in fat mass could be considered a clinical benefit related
to reduce of cardiovascular risk24. Mechanisms by which
CLAs might reduce fat mass include the inhibition of
adipogenesis, the suspension of lipogenesis25, the stimu-
lation of lipolysis, and the induction of apoptosis in
white adipose tissue26. 
In addition, the CLA group also experienced a signifi-
cant reduction in WHR, one of the variables most
strongly related to cardiovascular risk27. Furthermore,
CLA subjects experienced a significant reduction in
WC, a phenomenon also reported by Risérus et al
(2001)28. WC is a measure of central obesity an indepen-
dent risk factor for metabolic syndrome and its decrease
is therefore likely associated with a reduction in this risk.
The CLA group members also experienced a significant
decrease in WHR, one of the studied variables most
strongly related to cardiovascular risk27, as measured by
specific blood markers such as oxidised LDL-choles-
terol and triglycerides29. Another studies report that CLA
consumption reduces fat mass differently in different
parts of the body, with the largest reductions in the trunk
of people with signs of metabolic syndrome and, in legs
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Table IV
Blood parameters at the baseline and end of the experimental period in members of both treatment groups
CLA group Control group
(n = 22) (n = 16)
Chol-t (mg/dL) Week 0 207.48 ± 30.77 196.94 ± 31.01
Week 24 211.10 ± 33.94 205.70 ± 37.01
Variation 3.62 ± 20.16 8.76 ± 24.58
LDL-chol (mg/dL) Week 0 133.86 ± 29.20 148.04 ± 71.96
Week 24 137.14 ± 23.70 135.56 ± 30.57
Variation 3.29 ± 24.82 -12.46 ± 64.65
HDL-chol (mg/dL) Week 0 57.19 ± 20.00 50.31 ± 7.88
Week 24 54.24 ± 12.13 50.81 ± 6.60
Variation -2.95 ± 17.49 0.50 ± 4.10
TG (mg/dL) Week 0 92.67 ± 28.70 106.13 ± 52.51
Week 24 94.81 ± 30.04 96.81 ± 16.74
Variation 2.14 ± 35.54 -9.31 ± 54.72
Glu-AC (mg/dL) Week 0 91.05 ± 6.94 93.24 ± 6.60
Week 24 93.71 ± 6.50a 93.82 ± 8.95
Variation 2.76 ± 5.67 0.59 ± 9.57
Insulin (mUI/mL) Week 0 7.89 ± 5.09 7.46 ± 3.28
Week 24 7.17 ± 3.11 7.54 ± 5.13
Variation -0.72 ± 3.94 0.08 ± 4.16
HOMA index Week 0 1.77 ± 1.13 1.72 ± 0.76
Week 24 1.67 ± 0.79 1.78 ± 1.42
Variation -0.10 ± 0.81 0.07 ± 1.33
Leptin (ng/mL) Week 0 19.04 ± 6.72 23.21 ± 11.67
Week 24 15.73 ± 7.32 21.08 ± 16.28
Variation -3.31 ± 3.83 -2.13 ± 9.02
Adiponectin (μg/mL) Week 0 10.85 ± 6.59 8.83 ± 4.76
Week 24 10.56 ± 5.10 9.00 ± 5.50
Variation -0.29 ± 2.32 0.16 ± 1.19
CR-P (mg/L) Week 0 1.93 ± 2.00 3.50 ± 3.12
Week 24 2.83 ± 2.51 3.80 ± 3.35
Variation 0.90 ± 1.33 0.30 ± 2.10
PAI-1 (ng/mL) Week 0 4.52 ± 3.36 4.87 ± 3.12
Week 24 4.83 ± 2.60 6.93 ± 4.30
Variation -0.14 ± 2.69 2.07 ± 2.55
ALT (UI/L) Week 0 21.43 ± 10.98 17.75 ± 8.51 
Week 24 21.48 ± 12.57 18.31 ± 5.43
Variation 0.05 ± 9.24 0.56 ± 6.69
AST (UI/L) Week 0 20.67 ± 5.69 18.44 ± 5.24
Week 24 23.71 ± 13.83 19.69 ± 3.96
Variation 3.05 ± 13.68 1.25 ± 3.39
Creatinine (mg/dL) Week 0 0.81 ± 0.17 0.86 ± 0.15
Week 24 0.89 ± 0.16a 0.91 ± 0.17
Variation 0.07 ± 0.09 0.06 ± 0.12
Chol-t: total cholesterol. TG: triglycerides. Glu-AC: fasting glucose. HOMA: insulin resistance index. CR-P: C-reactive protein.
PAI-1: plasminogen activator inhibitor1. ALT: alanine aminotransferase. AST: aspartate aminotransferase.
asignificantly different with respect to values at the beginning of the study (p < 0.05).
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of overweight/obese people30. Shu-Chiun et al (2012)
demonstrated significantly decrease of body weight,
BMI, fat mass, fat percentage and subcutaneous fat mass
in overweight and grade I obese subjects supplemented
with a milk beverage enriched CLA (3.4 g/d) for 12
weeks31. Nevertheless in the present study, no diffe-
rences were observed (data not shown), probably
because none of the subjects were obese.
One of the plausible mechanisms by which CLA
may reduce body weight is via an increase in the meta-
bolic rate due to increased muscular mass and its asso-
ciated energy expenditure32,33. A number of studies
have shown that, parallel to the reduction in fat mass,
lean mass increase in subjects who consume CLAs. On
the other hand, in the present study the lean mass
remained stable in subjects. 
It should be remembered that the present subjects
maintained their normal dietary and exercise patterns.
It is therefore to be expected that the reduction in anth-
ropometric values and body composition be less than
those seen in studies involving CLA and a hypocaloric
diet and/or an exercise programme. 
Some studies suggest that CLA c9-t11 and t10-c12
have a negative effect on HDL-cholesterol, plasma
triglycerides, C-reactive protein, and plasminogen acti-
vator inhibitor-1, and therefore may increase the risk of
cardiovascular disease and even glucose intolerance
and diabetes mellitus type II34. In the present trial,
hepatic function markers; cardiovascular risk markers,
such as the blood lipid profile and the HOMA index;
and the inflammatory markers did not underwent signi-
ficant variation. The blood glucose and creatinine
values showed a significant increase in the CLA group,
but the values reached still remained within the normal
range defined for this target population34.
In summary, our results, in agreement with other
trials performed with the same product show a net
decrease of body weight, indicate a lack of adverse
effects and contribute to support the safety of the CLA
mixture (c9-t11 and t10-c12) as novel food ingredient
recently recognised by the European Food Safety
Authority in quantities up to 3.5 g day35. 
Conclusion
The daily consumption of skimmed milk enriched
with 3 g of a 1:1 mixture of c9-t11 and t10-c12 for 24
weeks led to a slight decrease in body weight and total
fat mass in healthy, overweight subjects who main-
tained habitual diets and exercise patterns. In this
context, further clinical trials should be encouraged,
including hypocaloric diet and regular physical exer-
cise to the co-treatment of overweight. 
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